<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Kiniksa-Pharmaceuticals-Ltd-Class-A-BMG5269C1010">Kiniksa Pharmaceuticals Ltd. Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/28/3282473/0/en/Kiniksa-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Recent-Portfolio-Execution.html">Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution</a>
    </div>

      <div class="me-0 me-md-5">
        – ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webc...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Kiniksa-Pharmaceuticals-Ltd-Class-A-BMG5269C1010">Kiniksa Pharmaceuticals Ltd. Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/23/3280354/0/en/Kiniksa-Pharmaceuticals-to-Report-First-Quarter-2026-Financial-Results-on-April-28-2026.html">Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Kiniksa-Pharmaceuticals-Ltd-Class-A-BMG5269C1010">Kiniksa Pharmaceuticals Ltd. Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/coverage/filings/2026/04/17/what-this-usd309k-kiniksa-insider-sale-might-signal-amid-a-120-stock-surge/">What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge</a>
    </div>

      <div class="me-0 me-md-5">
        The chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026. The director reported still holding 27,418 Class A ordinary shares after the transaction.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Kiniksa-Pharmaceuticals-Ltd-Class-A-BMG5269C1010">Kiniksa Pharmaceuticals Ltd. Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/08/3270058/0/en/Kiniksa-Pharmaceuticals-Launches-Targeted-Direct-To-Consumer-TV-Campaign-for-ARCALYST-rilonacept-in-Recurrent-Pericarditis.html">Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis</a>
    </div>

      <div class="me-0 me-md-5">
        – Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by clicking on  this link – LONDON, April 08, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing n...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Kiniksa-Pharmaceuticals-Ltd-Class-A-BMG5269C1010">Kiniksa Pharmaceuticals Ltd. Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/research/ibd-stock-of-the-day/biotech-stock-of-the-day-kiniksa-pharmaceuticals-knsa/">Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market</a>
    </div>

      <div class="me-0 me-md-5">
        The stock is one of only two in IBD&#39;s biotech group with highest-possible 99 Composite Ratings.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Kiniksa-Pharmaceuticals-Ltd-Class-A-BMG5269C1010">Kiniksa Pharmaceuticals Ltd. Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/news/ai-fueled-trio-among-top-five-stocks-near-buy-points/">AI-Fueled Trio Leads 5 Stocks To Watch Near Buy Points</a>
    </div>

      <div class="me-0 me-md-5">
        Top stocks near buy points this week include three lesser-known AI-adjacent plays.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Kiniksa-Pharmaceuticals-Ltd-Class-A-BMG5269C1010/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>